Your session is about to expire
← Back to Search
Dietary Supplement
Synaquell for Brain Function in Athletes
N/A
Waitlist Available
Led By Michael Stuart, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, postseason (approximately 6 months)
Summary
This trial is testing if the brain health supplement Synaquell can improve brain function in youth ice hockey players. The study will compare results from those taking Synaquell and others over several months using different brain health tests.
Who is the study for?
This trial is for medically cleared youth ice hockey players who speak English fluently. It's not suitable for those with pacemakers, defibrillators, in-ear hearing devices, skull implants, seizure history or allergies to SynaquellTM ingredients, rubbing alcohol or EEG gel.
What is being tested?
The study tests the effects of a dietary supplement called Synaquell(TM) on brain function in these athletes. Participants will either receive Synaquell(TM) or a placebo without knowing which one they are taking.
What are the potential side effects?
Potential side effects aren't specified but may relate to individual sensitivity to the ingredients of Synaquell(TM) or the placebo used in this research.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, postseason (approximately 6 months)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, postseason (approximately 6 months)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in N100 Amplitude
Change in N100 Latency
Change in N400 Amplitude
+4 moreSecondary study objectives
Change in King-Devick Test (KDT) scores
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Synaquell Male GroupExperimental Treatment1 Intervention
Male youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
Group II: Synaquell Female GroupExperimental Treatment1 Intervention
Female youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
Group III: Placebo Male GroupPlacebo Group1 Intervention
Male youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
Group IV: Placebo Female GroupPlacebo Group1 Intervention
Female youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Synaquell
2021
N/A
~140
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Nutritional supplements like Synaquell (TM) typically contain vitamins, minerals, and bioactive compounds that support brain health by enhancing cognitive function, protecting against oxidative stress, and improving brain metabolism. These mechanisms are important for healthy subjects as they help maintain optimal brain function, prevent cognitive decline, and enhance mental performance.
Potential role of phytochemicals in metabolic syndrome prevention and therapy.
Potential role of phytochemicals in metabolic syndrome prevention and therapy.
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,326 Previous Clinical Trials
3,059,401 Total Patients Enrolled
Michael Stuart, MDPrincipal InvestigatorMayo Clinic
3 Previous Clinical Trials
4,100 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You use a hearing aid or cochlear implant in your ear.You are allergic to the ingredients in SynaquellTM or the placebo.You have a medical record that shows you have hearing problems.You have metal or plastic implants in your skull.You have a history of seizures (epileptic fits).You are allergic to rubbing alcohol or the gel used for EEG tests.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo Male Group
- Group 2: Synaquell Male Group
- Group 3: Synaquell Female Group
- Group 4: Placebo Female Group
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger